Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Works matching IS 11707690 AND DT 2012 AND VI 30 AND IP 11
Results: 14
1
2
The burden of moderate to severe psoriasis: an overview.
- Published in:
- 2012
- By:
- Publication type:
- journal article
3
Losing sight of the wood for the trees: some issues in describing and valuing health, and another possible approach.
- Published in:
- 2012
- By:
- Publication type:
- journal article
4
The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
- Published in:
- 2012
- By:
- Publication type:
- journal article
5
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
- Published in:
- 2012
- By:
- Publication type:
- journal article
6
Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis.
- Published in:
- PharmacoEconomics, 2012, v. 30, n. 11, p. 981, doi. 10.2165/11599390-000000000-00000
- By:
- Publication type:
- Article
7
Cost Effectiveness of Hepatitis C-Related Interventions Targeting Substance Users and Other High-Risk Groups.
- Published in:
- PharmacoEconomics, 2012, v. 30, n. 11, p. 1015, doi. 10.2165/11597660-000000000-00000
- By:
- Publication type:
- Article
8
Losing Sight of the Wood for the Trees.
- Published in:
- PharmacoEconomics, 2012, v. 30, n. 11, p. 1035, doi. 10.2165/11593040-000000000-00000
- By:
- Publication type:
- Article
9
The General Public's Willingness to Pay for Tax Increases to Support Unrestricted Access to an Alzheimer's Disease Medication.
- Published in:
- PharmacoEconomics, 2012, v. 30, n. 11, p. 1085, doi. 10.2165/11594180-000000000-00000
- By:
- Publication type:
- Article
10
A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand.
- Published in:
- PharmacoEconomics, 2012, v. 30, n. 11, p. 1051, doi. 10.2165/11595270-000000000-00000
- By:
- Publication type:
- Article
11
The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes.
- Published in:
- PharmacoEconomics, 2012, v. 30, n. 11, p. 1067, doi. 10.2165/11595080-000000000-00000
- By:
- Publication type:
- Article
12
Erratum to Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.
- Published in:
- 2012
- By:
- Publication type:
- Erratum
13
The Burden of Moderate to Severe Psoriasis.
- Published in:
- PharmacoEconomics, 2012, v. 30, n. 11, p. 1005, doi. 10.2165/11591580-000000000-00000
- By:
- Publication type:
- Article
14
Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6-11 Years.
- Published in:
- PharmacoEconomics, 2012, v. 30, n. 11, p. 991, doi. 10.2165/11597160-000000000-00000
- By:
- Publication type:
- Article